MedChem Express

MedChem Express logo

MedChemExpress has an experienced team of custom synthesis chemists, led by an impressive group of Ph.D.'s. With this team, we have the capability of supporting all kinds of chemistry projects of multiple step syntheses of complex labeled molecules, including metabolites and steroids. Following scientific and technological innovation, challenging traditional thinking, MedChemExpress has always been committed to develop quality products that exceed international standards on cost and reliability, to create the most advanced synthetic route. With high experiences in preparing a large numbers of different biologically active molecules, we provide rapid synthesis of new products. That is why we can consistently deliver your custom synthesis compounds faster than any other company.

Company Website

Product Listing

Y06036 100mg  | ≥98%

MedChem Express

Y06036 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with Kd value of 82 nM[1]. Antitumor activity[1]. In Vitro: Y06036 (0.001-100 nM, 96 hours for LNCaP, C4-2B, and 22Rv1 cells; 144 hours for VCaP cells) exhibits low micromolar or nanomolar potencies (IC50: 0.29-2.6 μΜ) in the four androgen receptor (AR)-positive […]

More Information Supplier Page

Y06036 10mg  | ≥98%

MedChem Express

Y06036 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with Kd value of 82 nM[1]. Antitumor activity[1]. In Vitro: Y06036 (0.001-100 nM, 96 hours for LNCaP, C4-2B, and 22Rv1 cells; 144 hours for VCaP cells) exhibits low micromolar or nanomolar potencies (IC50: 0.29-2.6 μΜ) in the four androgen receptor (AR)-positive […]

More Information Supplier Page

Y06036 5mg  | ≥98%

MedChem Express

Y06036 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with Kd value of 82 nM[1]. Antitumor activity[1]. In Vitro: Y06036 (0.001-100 nM, 96 hours for LNCaP, C4-2B, and 22Rv1 cells; 144 hours for VCaP cells) exhibits low micromolar or nanomolar potencies (IC50: 0.29-2.6 μΜ) in the four androgen receptor (AR)-positive […]

More Information Supplier Page

Y06036 10mM/1mL  | ≥98%

MedChem Express

Y06036 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with Kd value of 82 nM[1]. Antitumor activity[1]. In Vitro: Y06036 (0.001-100 nM, 96 hours for LNCaP, C4-2B, and 22Rv1 cells; 144 hours for VCaP cells) exhibits low micromolar or nanomolar potencies (IC50: 0.29-2.6 μΜ) in the four androgen receptor (AR)-positive […]

More Information Supplier Page

Y06137 50mg  | ≥98%

MedChem Express

Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM[1]. Antitumor activity[1]. In Vitro: Y06137 (0.001-100 nM, 96 hours for LNCaP, C4-2B, and 22Rv1 cells; 144 hours for VCaP cells) exhibits low micromolar or nanomolar potencies (IC50: 0.29-2.6 μΜ) in the four androgen receptor (AR)-positive […]

More Information Supplier Page

Y06137 100mg  | ≥98%

MedChem Express

Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM[1]. Antitumor activity[1]. In Vitro: Y06137 (0.001-100 nM, 96 hours for LNCaP, C4-2B, and 22Rv1 cells; 144 hours for VCaP cells) exhibits low micromolar or nanomolar potencies (IC50: 0.29-2.6 μΜ) in the four androgen receptor (AR)-positive […]

More Information Supplier Page

Y06137 5mg  | ≥98%

MedChem Express

Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM[1]. Antitumor activity[1]. In Vitro: Y06137 (0.001-100 nM, 96 hours for LNCaP, C4-2B, and 22Rv1 cells; 144 hours for VCaP cells) exhibits low micromolar or nanomolar potencies (IC50: 0.29-2.6 μΜ) in the four androgen receptor (AR)-positive […]

More Information Supplier Page

Y06137 10mg  | ≥98%

MedChem Express

Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM[1]. Antitumor activity[1]. In Vitro: Y06137 (0.001-100 nM, 96 hours for LNCaP, C4-2B, and 22Rv1 cells; 144 hours for VCaP cells) exhibits low micromolar or nanomolar potencies (IC50: 0.29-2.6 μΜ) in the four androgen receptor (AR)-positive […]

More Information Supplier Page

Y06137 25mg  | ≥98%

MedChem Express

Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM[1]. Antitumor activity[1]. In Vitro: Y06137 (0.001-100 nM, 96 hours for LNCaP, C4-2B, and 22Rv1 cells; 144 hours for VCaP cells) exhibits low micromolar or nanomolar potencies (IC50: 0.29-2.6 μΜ) in the four androgen receptor (AR)-positive […]

More Information Supplier Page

Y15 10mM/1mL  | ≥98%

MedChem Express

Y15 is a direct and specific inhibitor of FAK auto-phosphorylation. IC50 & Target: FAK[1] In Vitro: Y15 directly blocks autophosphorylation activity of FAK. Y15 inhibits Y397 phosphorylation of FAK starting at 0.1 μM in Panc-1 cells. At a dose of 100 μM, Y15 has the same or better inhibition as TAE226. Of note, total FAK […]

More Information Supplier Page

Y15 10mg  | ≥98%

MedChem Express

Y15 is a direct and specific inhibitor of FAK auto-phosphorylation. IC50 & Target: FAK[1] In Vitro: Y15 directly blocks autophosphorylation activity of FAK. Y15 inhibits Y397 phosphorylation of FAK starting at 0.1 μM in Panc-1 cells. At a dose of 100 μM, Y15 has the same or better inhibition as TAE226. Of note, total FAK […]

More Information Supplier Page

Y15 50mg  | ≥98%

MedChem Express

Y15 is a direct and specific inhibitor of FAK auto-phosphorylation. IC50 & Target: FAK[1] In Vitro: Y15 directly blocks autophosphorylation activity of FAK. Y15 inhibits Y397 phosphorylation of FAK starting at 0.1 μM in Panc-1 cells. At a dose of 100 μM, Y15 has the same or better inhibition as TAE226. Of note, total FAK […]

More Information Supplier Page

Y16 10mM/1mL  | ≥98%

MedChem Express

Y16 is an inhibitor of G-protein–coupled Rho GEFs; works synergistically with Rhosin/G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions. IC50 value: Target: RhoA inhibitor Y16 binds to this catalytic fragment of LARG with a Kd of ~76 ± 8 nM. Y16 was able to inhibit the GDP dissociation from RhoA catalyzed by […]

More Information Supplier Page

Y16 5mg  | ≥98%

MedChem Express

Y16 is an inhibitor of G-protein–coupled Rho GEFs; works synergistically with Rhosin/G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions. IC50 value: Target: RhoA inhibitor Y16 binds to this catalytic fragment of LARG with a Kd of ~76 ± 8 nM. Y16 was able to inhibit the GDP dissociation from RhoA catalyzed by […]

More Information Supplier Page

Y16 10mg  | ≥98%

MedChem Express

Y16 is an inhibitor of G-protein–coupled Rho GEFs; works synergistically with Rhosin/G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions. IC50 value: Target: RhoA inhibitor Y16 binds to this catalytic fragment of LARG with a Kd of ~76 ± 8 nM. Y16 was able to inhibit the GDP dissociation from RhoA catalyzed by […]

More Information Supplier Page

Yangonin 5mg  | ≥98%

MedChem Express

Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC50 and a Ki of 1.79 ± 0.53 μM and 0.72±0.21 μM, respectively. IC50 & Target: IC50: 1.79±0.53 μM (hCB1 receptor), >10 μM (hCB2 receptor)[1] Ki: 0.72±0.21 μM (hCB1 receptor), >10 μM (hCB2 receptor)[1] RelA/p65[2] In Vitro: Yangonin is one of the six […]

More Information Supplier Page

Yangonin 10mg  | ≥98%

MedChem Express

Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC50 and a Ki of 1.79 ± 0.53 μM and 0.72±0.21 μM, respectively. IC50 & Target: IC50: 1.79±0.53 μM (hCB1 receptor), >10 μM (hCB2 receptor)[1] Ki: 0.72±0.21 μM (hCB1 receptor), >10 μM (hCB2 receptor)[1] RelA/p65[2] In Vitro: Yangonin is one of the six […]

More Information Supplier Page

YF-2 5mg  | ≥98%

MedChem Express

YF-2 is a highly selective, blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC50s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer’s disease[1]. IC50 & Target: EC50: 2.75 μM (CBP), 29.04 μM (PCAF), 49.31 μM (GCN5)[1] In Vitro: […]

More Information Supplier Page

YF-2 100mg  | ≥98%

MedChem Express

YF-2 is a highly selective, blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC50s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer’s disease[1]. IC50 & Target: EC50: 2.75 μM (CBP), 29.04 μM (PCAF), 49.31 μM (GCN5)[1] In Vitro: […]

More Information Supplier Page

YF-2 10mg  | ≥98%

MedChem Express

YF-2 is a highly selective, blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC50s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer’s disease[1]. IC50 & Target: EC50: 2.75 μM (CBP), 29.04 μM (PCAF), 49.31 μM (GCN5)[1] In Vitro: […]

More Information Supplier Page

YF-2 50mg  | ≥98%

MedChem Express

YF-2 is a highly selective, blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC50s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer’s disease[1]. IC50 & Target: EC50: 2.75 μM (CBP), 29.04 μM (PCAF), 49.31 μM (GCN5)[1] In Vitro: […]

More Information Supplier Page

YF-2 10mM/1mL  | ≥98%

MedChem Express

YF-2 is a highly selective, blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC50s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer’s disease[1]. IC50 & Target: EC50: 2.75 μM (CBP), 29.04 μM (PCAF), 49.31 μM (GCN5)[1] In Vitro: […]

More Information Supplier Page

YH239-EE 10mM/1mL  | ≥98%

MedChem Express

YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent IC50 value: Target: MDM2/p53 YH239-EE inhibits the growth of OCI-AML-3 cells with wild type p53 by inhibiting the p53-MDM2 interaction. YH239-EE induces cell cycle arrest and causes potent cell apoptosis via activation of p53 and downstream targets […]

More Information Supplier Page

YH239-EE 50mg  | ≥98%

MedChem Express

YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent IC50 value: Target: MDM2/p53 YH239-EE inhibits the growth of OCI-AML-3 cells with wild type p53 by inhibiting the p53-MDM2 interaction. YH239-EE induces cell cycle arrest and causes potent cell apoptosis via activation of p53 and downstream targets […]

More Information Supplier Page

YH239-EE 10mg  | ≥98%

MedChem Express

YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent IC50 value: Target: MDM2/p53 YH239-EE inhibits the growth of OCI-AML-3 cells with wild type p53 by inhibiting the p53-MDM2 interaction. YH239-EE induces cell cycle arrest and causes potent cell apoptosis via activation of p53 and downstream targets […]

More Information Supplier Page

YHO-13177 5mg  | ≥98%

MedChem Express

YHO-13177 is a potent and specific inhibitor of BCRP; potentiated the cytotoxicity of SN-38 in cancer cells and no effect on P-glycoprotein–mediated paclitaxel resistance in MDR1-transduced human leukemia K562 cells. IC50 value: Target: BCRP inhibitor in vitro: YHO-13177 potentiated the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells […]

More Information Supplier Page

YHO-13177 10mg  | ≥98%

MedChem Express

YHO-13177 is a potent and specific inhibitor of BCRP; potentiated the cytotoxicity of SN-38 in cancer cells and no effect on P-glycoprotein–mediated paclitaxel resistance in MDR1-transduced human leukemia K562 cells. IC50 value: Target: BCRP inhibitor in vitro: YHO-13177 potentiated the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells […]

More Information Supplier Page

YHO-13177 10mM/1mL  | ≥98%

MedChem Express

YHO-13177 is a potent and specific inhibitor of BCRP; potentiated the cytotoxicity of SN-38 in cancer cells and no effect on P-glycoprotein–mediated paclitaxel resistance in MDR1-transduced human leukemia K562 cells. IC50 value: Target: BCRP inhibitor in vitro: YHO-13177 potentiated the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells […]

More Information Supplier Page

YHO-13177 50mg  | ≥98%

MedChem Express

YHO-13177 is a potent and specific inhibitor of BCRP; potentiated the cytotoxicity of SN-38 in cancer cells and no effect on P-glycoprotein–mediated paclitaxel resistance in MDR1-transduced human leukemia K562 cells. IC50 value: Target: BCRP inhibitor in vitro: YHO-13177 potentiated the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells […]

More Information Supplier Page

YHO-13177 100mg  | ≥98%

MedChem Express

YHO-13177 is a potent and specific inhibitor of BCRP; potentiated the cytotoxicity of SN-38 in cancer cells and no effect on P-glycoprotein–mediated paclitaxel resistance in MDR1-transduced human leukemia K562 cells. IC50 value: Target: BCRP inhibitor in vitro: YHO-13177 potentiated the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells […]

More Information Supplier Page

YHO-13351 10mg  | ≥98%

MedChem Express

YHO-13351 is the water-soluble prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP. IC50 value: Target: BCRP inhibitor in vitro: YHO-13177 potentiated the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells and SN-38–resistant human lung cancer A549 (A549/SN4) cells that express BCRP, but had little […]

More Information Supplier Page

YHO-13351 5mg  | ≥98%

MedChem Express

YHO-13351 is the water-soluble prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP. IC50 value: Target: BCRP inhibitor in vitro: YHO-13177 potentiated the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells and SN-38–resistant human lung cancer A549 (A549/SN4) cells that express BCRP, but had little […]

More Information Supplier Page

YHO-13351 (free base) 10mM/1mL  | ≥98%

MedChem Express

YHO-13351 (free base) is the water-soluble prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP. IC50 value: Target: BCRP inhibitor in vitro: YHO-13177 potentiates the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells and SN-38-resistant human lung cancer A549 (A549/SN4) cells that express BCRP, but […]

More Information Supplier Page

YHO-13351 (free base) 10mg  | ≥98%

MedChem Express

YHO-13351 (free base) is the water-soluble prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP. IC50 value: Target: BCRP inhibitor in vitro: YHO-13177 potentiates the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells and SN-38-resistant human lung cancer A549 (A549/SN4) cells that express BCRP, but […]

More Information Supplier Page

YHO-13351 (free base) 5mg  | ≥98%

MedChem Express

YHO-13351 (free base) is the water-soluble prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP. IC50 value: Target: BCRP inhibitor in vitro: YHO-13177 potentiates the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells and SN-38-resistant human lung cancer A549 (A549/SN4) cells that express BCRP, but […]

More Information Supplier Page

YHO-13351 (free base) 50mg  | ≥98%

MedChem Express

YHO-13351 (free base) is the water-soluble prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP. IC50 value: Target: BCRP inhibitor in vitro: YHO-13177 potentiates the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells and SN-38-resistant human lung cancer A549 (A549/SN4) cells that express BCRP, but […]

More Information Supplier Page

YHO-13351 (free base) 100mg  | ≥98%

MedChem Express

YHO-13351 (free base) is the water-soluble prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP. IC50 value: Target: BCRP inhibitor in vitro: YHO-13177 potentiates the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells and SN-38-resistant human lung cancer A549 (A549/SN4) cells that express BCRP, but […]

More Information Supplier Page

YK-4-279 10mg  | ≥98%

MedChem Express

YK 4-279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWS-FLI1. YK-4-279 inhibits Ewing’s sarcoma family tumor (ESFT) cell growth; YK-4-279 induces apoptosis. IC50 value: Target: RNA Helicase A ES-FLI1 is an oncogenic fusion protein found in Ewing’s sarcoma, a family of undifferentiated tumors that occur throughout the body. […]

More Information Supplier Page

YK-4-279 50mg  | ≥98%

MedChem Express

YK 4-279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWS-FLI1. YK-4-279 inhibits Ewing’s sarcoma family tumor (ESFT) cell growth; YK-4-279 induces apoptosis. IC50 value: Target: RNA Helicase A ES-FLI1 is an oncogenic fusion protein found in Ewing’s sarcoma, a family of undifferentiated tumors that occur throughout the body. […]

More Information Supplier Page

YK-4-279 100mg  | ≥98%

MedChem Express

YK 4-279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWS-FLI1. YK-4-279 inhibits Ewing’s sarcoma family tumor (ESFT) cell growth; YK-4-279 induces apoptosis. IC50 value: Target: RNA Helicase A ES-FLI1 is an oncogenic fusion protein found in Ewing’s sarcoma, a family of undifferentiated tumors that occur throughout the body. […]

More Information Supplier Page

YK-4-279 10mM/1mL  | ≥98%

MedChem Express

YK 4-279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWS-FLI1. YK-4-279 inhibits Ewing’s sarcoma family tumor (ESFT) cell growth; YK-4-279 induces apoptosis. IC50 value: Target: RNA Helicase A ES-FLI1 is an oncogenic fusion protein found in Ewing’s sarcoma, a family of undifferentiated tumors that occur throughout the body. […]

More Information Supplier Page

YK11 5mg  | ≥98%

MedChem Express

YK11 is a partial agonist of androgen receptor, with osteogenic activity. IC50 & Target: Androgen receptor[1] In Vitro: YK11 is a partial agonist of androgen receptor, and induces myogenic differentiation of C2C12 Cells at 500 nM via Fst mRNA upregulation by AR. YK11 enhances Myf5 and myogenin mRNA expression, but requires high concentrations (YK11, 100 nM […]

More Information Supplier Page

YK11 50mg  | ≥98%

MedChem Express

YK11 is a partial agonist of androgen receptor, with osteogenic activity. IC50 & Target: Androgen receptor[1] In Vitro: YK11 is a partial agonist of androgen receptor, and induces myogenic differentiation of C2C12 Cells at 500 nM via Fst mRNA upregulation by AR. YK11 enhances Myf5 and myogenin mRNA expression, but requires high concentrations (YK11, 100 nM […]

More Information Supplier Page

YK11 25mg  | ≥98%

MedChem Express

YK11 is a partial agonist of androgen receptor, with osteogenic activity. IC50 & Target: Androgen receptor[1] In Vitro: YK11 is a partial agonist of androgen receptor, and induces myogenic differentiation of C2C12 Cells at 500 nM via Fst mRNA upregulation by AR. YK11 enhances Myf5 and myogenin mRNA expression, but requires high concentrations (YK11, 100 nM […]

More Information Supplier Page

YK11 100mg  | ≥98%

MedChem Express

YK11 is a partial agonist of androgen receptor, with osteogenic activity. IC50 & Target: Androgen receptor[1] In Vitro: YK11 is a partial agonist of androgen receptor, and induces myogenic differentiation of C2C12 Cells at 500 nM via Fst mRNA upregulation by AR. YK11 enhances Myf5 and myogenin mRNA expression, but requires high concentrations (YK11, 100 nM […]

More Information Supplier Page

YK11 10mg  | ≥98%

MedChem Express

YK11 is a partial agonist of androgen receptor, with osteogenic activity. IC50 & Target: Androgen receptor[1] In Vitro: YK11 is a partial agonist of androgen receptor, and induces myogenic differentiation of C2C12 Cells at 500 nM via Fst mRNA upregulation by AR. YK11 enhances Myf5 and myogenin mRNA expression, but requires high concentrations (YK11, 100 nM […]

More Information Supplier Page

YK11 10mM/1mL  | ≥98%

MedChem Express

YK11 is a partial agonist of androgen receptor, with osteogenic activity. IC50 & Target: Androgen receptor[1] In Vitro: YK11 is a partial agonist of androgen receptor, and induces myogenic differentiation of C2C12 Cells at 500 nM via Fst mRNA upregulation by AR. YK11 enhances Myf5 and myogenin mRNA expression, but requires high concentrations (YK11, 100 nM […]

More Information Supplier Page

YKL-05-099 10mM/1mL  | ≥98%

MedChem Express

YKL-05-099 is a salt-inducible kinase (SIK) probe; inhibits SIK2 with an IC50 of 40 nM. IC50 & Target: IC50: 40 nM (SIK2)[1] In Vitro: YKL-05-099 has slightly less potent SIK2-inhibitory (IC50=40 nM) and IL-10-enhancing activities (EC50=460 nM). YKL-05-099 binds to SIK1 and SIK3 with IC50s of 10 and 30 nM, respectively, in a competitive binding […]

More Information Supplier Page

YKL-05-099 5mg  | ≥98%

MedChem Express

YKL-05-099 is a salt-inducible kinase (SIK) probe; inhibits SIK2 with an IC50 of 40 nM. IC50 & Target: IC50: 40 nM (SIK2)[1] In Vitro: YKL-05-099 has slightly less potent SIK2-inhibitory (IC50=40 nM) and IL-10-enhancing activities (EC50=460 nM). YKL-05-099 binds to SIK1 and SIK3 with IC50s of 10 and 30 nM, respectively, in a competitive binding […]

More Information Supplier Page